名为LIBERATE-1的试验正在澳大利亚进行，标志着Vivani专有NanoPortal™药物植入技术的首次应用。该试验旨在评估exenatide植入剂在超重或肥胖参与者中的安全性、耐受性和药代动力学特征，以体重变化作为主要衡量指标。

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to ...

Exenatide is ultimately a diabetes drug. It plays around with insulin in the body more than anything else, but at least one study has found the drug could help patients with AD who previously took ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...

These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Sorry, we have no data ...

Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 and ...

Type 2 diabetes is a widespread condition where the body struggles to use or produce insulin effectively, leading to high ...

Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company developing novel, ...

No drug stops that happening. In the trial, half of patients were given the diabetes drug exenatide and the rest were given a placebo (dummy treatment). All the patients stayed on their usual ...

Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant.